

November 18, 2025

To,

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

National Stock Exchange of India Limited

Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East),
Mumbai - 400 051

Scrip code: 512529

Scrip code: SEQUENT

Dear Sir/ Madam,

Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Ref: Composite scheme of amalgamation amongst Sequent Scientific Limited ("Company"), Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, S.V. Labs Private Limited, Vindhya Organics Private Limited, Viyash Life Sciences Private Limited, Geninn Life Sciences Private Limited, Sequent Research Limited and their respective shareholders and the creditors ("Scheme")

With reference to the above, and in furtherance of our previous disclosures dated September 26, 2024, January 21, 2025, May 26, 2025, and August 30, 2025, we would like to inform you that the Hon'ble National Company Law Tribunal, Hyderabad Bench ("**Hon'ble Tribunal**") has at the hearing held today i.e. November 18, 2025 allowed the petition and pronounced the order for sanctioning the Scheme.

A written order of the Hon'ble Tribunal sanctioning the Scheme ("**Order**") is awaited and will be disclosed upon the Order becoming available on the website of the Hon'ble Tribunal.

The companies involved in the Scheme shall take necessary actions in accordance with the Scheme to make the Scheme effective. The Company shall inform the relevant dates under the Scheme, including the Effective Date 1 and Effective Date 2 (*as defined in the Scheme*) in due course for further public dissemination in accordance with applicable law and as and when the conditions for effectiveness are fulfilled. The Appointed Date of the Scheme is April 1, 2025.

Pursuant to the above, please find enclosed herewith Press Release and an updated version of the Investor Presentation shared by the Company.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For **Sequent Scientific Limited**

Yoshita Vora

Company Secretary & Compliance Officer

Encl: As above

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in

Press Release

SeQuent Scientific and Viyash Lifesciences Receive NCLT Approval for Transformational Merger

- **Combined Strengths Poised to Create a Global Animal Health Powerhouse**
- **Q2 FY25–26: Combined Sales Up 16%, EBITDA Surges 76%, underscoring the operational and strategic synergies emerging from the merger**

Mumbai, 18 November 2025 : SeQuent Scientific Ltd. (“SeQuent”), a leading player in the global Animal Health industry, and Viyash Lifesciences Private Limited (“Viyash”), an integrated global pharmaceutical company, announced today that the National Company Law Tribunal (NCLT) has allowed the petition and approved the Scheme of merger between SeQuent and the Viyash group of companies. The NCLT approval marks the beginning of a new chapter for the combined entity, and represents a fundamental transformation to leapfrog into the next orbit of the global animal health market. The combined financial performance of the companies with aggregate H1FY26 revenues of INR 16.5bn and aggregate H1FY26 EBITDA of INR 3.2bn, with a Net Debt to EBITDA ratio of 0.7x, represents significant scale as the largest animal health player from India.

As highlighted earlier, the combined entity is aligned to capitalise on two major long-term industry opportunities:

1. Global, fast-growing Companion (Pet) Animal Health segment – The inherent growth in the market provides a large opportunity, driven by increased pet adoption and emerging treatments for Bone & Joint disease, Dermatitis, Diabetes, Cardiology and Oncology, similar to human pharmaceutical applications.
2. Genericization of Animal Health, which lags significantly behind Human Health – This provides a substantial opportunity for the combined company to leverage its technical strengths in APIs and Formulations. In addition, the advanced capabilities in R&D would help strengthen its fast-growing CDMO business.

This merger not only delivers the necessary scale and capabilities for accelerating organic growth in the Animal Health market, but also provides financial resilience, stability, and management bandwidth to rejuvenate SeQuent’s inorganic growth engine.

Dr. Haribabu Bodepudi, Founder and CEO, Viyash, said, *“This merger creates the platform to deliver world-class solutions for our customers. With our strengths in R&D, custom development capabilities, manufacturing capacities, and a streamlined supply chain, we would emerge as an innovative and reliable partner for our customers across the world. Over the last few months, we have developed a comprehensive plan for integration which leverages synergies for growth and capability. The momentum reflected in our recent results is only the beginning”*

Commenting on the merger, **Mr. Rajaram Narayanan, Managing Director and CEO of SeQuent,** said, *“We are pleased to receive the approval from the Hon’ble NCLT, marking the start of a transformative journey for the combined entity. There are significant opportunities to provide relevant, differentiated and quality care for animals. With this merger, the Company will be uniquely positioned to build a world-class business and deliver on the requirements of pet owners, farmers and animal health professionals. Together, we are building a company that will set new benchmarks in quality, innovation, and customer trust.”*

About SeQuent Scientific

SeQuent Scientific Limited (BSE: 512529, NSE: SEQUENT), headquartered in India, operates in the Animal Health market with a global footprint. SeQuent has seven manufacturing facilities based in India, Spain, Brazil and Turkey with approvals from international regulatory bodies, including USFDA, EUGMP, WHO, TGA, etc. SeQuent currently produces APIs and animal health formulations in over 100 countries and has more than 1,500 employees.

About Viyash Lifesciences

Viyash Lifesciences is an integrated end-to-end pharmaceutical company with a presence across niche formulations, APIs and advanced intermediates. Viyash has an R&D team of 200+ scientists and has 9 USFDA-approved plants, signifying strong R&D and manufacturing capabilities. Viyash serves customers across 150+ countries.

For further information, please contact:

Yoshita Vora Company Secretary SeQuent Scientific Limited Email: investorrelations@sequent.in	Janaki S Company Secretary Viyash Lifesciences Private Limited	Abhishek Singhal Investor Relations Consultant Email: abhishek@arunya.co.in
---	---	---

A large, stylized illustration of a globe in light blue and white. On top of the globe, there are several animals rendered in a low-poly, geometric style using shades of green, blue, and purple. These include a large bull, a horse, a dog, and two smaller animals that look like goats or sheep.

INVESTOR PRESENTATION

Q2 FY26

SEQUENT SCIENTIFIC LIMITED

18th Nov 2025

Steadfast commitment to improvement in business fundamentals



“The results of Q2 FY 25-26 and the first half FY 25-26 reinforce the transformational journey undertaken by the company. Revenue, margins and profits have continued to show healthy growth on the back of new product introductions, superior product mix and cost improvement programs. The merger with Viyash Life Sciences is almost concluded. We are already seeing the benefits in manufacturing synergies, R&D programs and customer leads. Viyash continues to deliver market beating performance in new filings, sales and margins. The merged entity is now well positioned to build new revenue streams, in addition to accelerating growth of existing businesses.”

Rajaram Narayanan
Sequent Scientific Limited

Dr Hari Babu Bodepudi
Viyash Life Sciences Limited

Q2FY26 Combined Performance



Q2 FY26 Performance Highlights


Revenues




EBITDA¹



EBITDA margin



Net Debt to LTM EBITDA¹



Broad based revenue growth across all businesses

All values in ₹ Mn



Revenue Distribution	Q2 FY26	Q2 FY25	YoY Gr%	Q1 FY26	QnQ Gr%	H1 FY26	H1 FY25	YoY Gr%
Formulations	3,364	2,836	18.6%	3,383	<i>(0.5%)</i>	6,747	5,837	15.6%
Europe	1,533	1,335	14.8%	1,640	<i>(6.5%)</i>	3,172	2,910	9.0%
Emerging Markets	1,469	1,160	26.7%	1,480	<i>(0.7%)</i>	2,949	2,342	25.9%
India	362	341	6.2%	263	37.8%	625	585	6.8%
APIs	830	773	7.3%	1,054	<i>(21.3%)</i>	1,884	1,697	11.0%
Other Sales	13	22	<i>(40.7%)</i>	15	<i>(10.3%)</i>	28	64	<i>(56.5%)</i>
Global Sales	4,207	3,631	15.9%	4,451	<i>(5.5%)</i>	8,659	7,598	14.0%
One Offs #		13		<i>(56)</i>		-56	-74	
Adjustment* - Ind AS 29*	33	43		19		51	64	
Sequent Sales	4,240	3,686	15.0%	4,414	<i>(3.9%)</i>	8,654	7,589	14.0%
Viyash Sales	4,281	3,632	17.8%	3,527	21.4%	7,808	7,032	11.0%
Overall Sales	8,521	7,319	16.4%	7,941	7.3%	16,462	14,621	12.6%

*Adjustment on account of hyperinflation in Turkey as per Ind AS 29

Provision for customer claim on shipments in prior years

Note: Financials presented are Pro forma financials (unaudited) for guidance on combined performance without incorporating any merger-related adjustments

H1 FY26 Performance Highlights

All values in ₹ Mn


Revenues



EBITDA¹



EBITDA margin



Net Debt to LTM EBITDA¹



Combined P&L Snapshot

Particulars	Q2 FY26	Q2 FY25	YoY %	H1FY26	FY25
Revenue	8,521	7,319	16.4%	16,462	30,094
Gross Profit	4,723	3,741		8,838	15,366
<i>Gross margin %</i>	<i>55.4%</i>	<i>51.1%</i>		<i>53.7%</i>	<i>51.1%</i>
EBITDA	1,890	1,076	75.6%	3,180	4,539
<i>EBITDA margin %</i>	<i>22.2%</i>	<i>14.7%</i>		<i>19.3%</i>	<i>15.1%</i>
Recurring Depreciation and Amortization	(346)	(345)		(623)	(1,309)
One Off Amortization	(245)	(236)		(524)	(1,079)
EBIT	1,299	495		2,033	2,151
Other Income	31	106		93	329
ESOP	(100)	(256)		(230)	(406)
Exchange Gain / (Loss)	(7)	(14)		(10)	(80)
Ind AS 29 Adjustment	(7)	25		30	29
Exceptions	(17)	(72)		(29)	(1,029)
Finance Cost	(175)	(208)		(379)	(864)
PBT	1,024	77		1,507	130
Tax	(295)	(96)		(410)	26
PAT	729	(19)		1,098	156

Key Notes :

ESOP cost, Exceptional items and amortization of acquisition intangibles are non-cash or non-recurring accounting items that pertain to prior period events:

- Exceptional Items include cost of accelerated vesting for share warrants, call option charge, merger expenses and provision for a contractual one-time bonus payable at Viyash
- Amortization of acquisition intangibles in Viyash is on account of intangibles created during acquisitions done in FY22. This accounting amortization will continue till FY27

Combined Balance Sheet Snapshot

All values in ₹ Mn

Particulars	Combined As of 30 Sep 2025
Shareholders' Funds	26,146
Minority Interest	1,674
Net Debt	4,095
Other Non current Liabilities	2,362
Total Liabilities	34,276
Tangible Assets	11,930
Intangible Assets	1,485
Goodwill	8,303
Working Capital	9,672
Other Non current Asset	2,609
Net assets held for Sale	277
Total Assets	34,276

Key Ratios	Combined
Net Debt to Equity	0.2x
Net Debt to EBITDA	0.7x
RoCE ex Goodwill (%)	13%
RoE ex-Goodwill (%)	13%


Note: Financials presented are Pro forma financials (unaudited) for guidance on combined performance without incorporating any merger-related adjustments

1. Exceptional Items include cost of accelerated vesting for share warrants, call option charge, merger expenses (Viyash) and one-time contractual bonus payable to Viyash management (Viyash) 2. PAT adjusted for Amortization of acquisition intangibles and Exceptional Items (net of tax)

3. Adjusted for ESOP costs

Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers

Merger Update



Merger – Process Update

Merger process status update

- NCLT approval order reserved on Oct 31, 2025; order pronounced on Nov 18, 2025
- **Focus on synergy realization for next 12 months**



Synergy Update

Area	Key Ideation Action Items	Progress
R&D	- R&D teams to be co-located; to work collaboratively on NPD & cost improvement - QA & Testing to be moved on-site from 3rd party location	API R&D fully integrated leading to accelerated development 4 New animal health products developed/validated 3 Cost improvement projects completed Regulatory filing in progress
Manufacturing	- Utilize available low-cost capacity through the group; action plan created - Procurement synergies identified	6 Intermediates validated at Viyash sites, which were procured from external sources - New production block created in short time to improve capacity, productivity and cost of Sequent products. - One large volume Sequent API validated & filing under progress
Sales	Leverage key relationships of both companies; outreach & discussion plan prepared	Business teams working closely to identify opportunities to cross sell
Others	Assess shared administrative & support functions	All support functions integration initiated

In advanced stages


New production block commissioned in record time



New production block created in short time to improve capacity, productivity and cost of Sequent products

One large volume Sequent API validated & filing under progress

Business Update - Sequent



SeQuent: Q2FY26 Business Performance

All values in ₹ Mn



Formulations

- ✓ **Europe:** Significant growth in Spain with good exports performance
- ✓ **Emerging Markets:**
 - Launched Tulaject in Brazil & received MA for Mexico market
 - R&D infrastructure expanded
- ✓ **India:** Business beginning to accelerate as field team expansion ramps up



1,000+
FDFs



90+
Countries



5
Manufacturing
Facilities

API

- ✓ Business momentum continues, ~7% YoY growth
- ✓ **Launched a product for the US market**
- ✓ Completed successful audits for a large customers with no critical observations
- ✓ **SRL USFDA audit** completed – EIR awaited



35
APIs




50+
Countries



2
Manufacturing
facilities

Business Update - Viyash



Viyash: Q2 FY26 Key growth drivers



New products launches

Focus on CDMO business

Improved product mix

Network optimisation for better efficiencies

Backward and Forward integration

Key updates from Q2 FY26



Facility Inspections

- ✓ **4** Regulatory Audits
- ✓ **56** Customer audits
- ✓ **1** US FDA EIR



Products Filed

- ✓ **9 Filings** – SFDA(3), EDQM (1) TGA (1), EDMF (2), WHO (1), TW (1)
- ✓ **FDFs -Nil**



Regulatory Approvals

- ✓ **2 APIs**: (USDMF-1 ; EDQM-1)



Validations Completed

- ✓ **3 APIs**



Launches

- ✓ **2 FDFs** (US)
- ✓ **2 APIs**



R&D Pipeline

- ✓ **16+** Products

For details, feel free to contact:

Yoshita Vora

Company Secretary

 +91 22 4111 4777

 investorrelations@sequent.in

Abhishek Singhal

Investor Relations Consultant

 abhishek@arunya.co.in

***Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39,
Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana***

Websites: www.sequent.in, www.alivira.co | CIN: L99999TS1985PLC196357 | BSE Code:512529 | NSE: SEQUENT

ISIN: INE807F01027

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

Thank You

